Once exclusive to infant formula, human milk oligosaccharides are now crossing over into foods, beverages and nutraceuticals for all ages. As science deciphers their gut-health and immune-supporting properties, manufacturers are tuning in – and market data reveals a wave of opportunity. Alex Summers reports.
The rise of human milk oligosaccharides (HMOs) in the functional ingredients arena feels like a well-timed plot twist: simple sugars, indigestible to humans, now steering big conversations in gut health, immunity and product innovation across food and nutrition sectors. Scientists once hailed HMOs as nature’s built-in prebiotics for infants. Today, their cameo in adult wellness formulations suggests they’ve become the protagonists of a new health narrative. Human milk is part science and part art. Among its components lies a further treasure trove – HMOs, the third-most abundant solid component in human milk, after lactose and lipids. Their twist? They sail right through the infant digestive tract to nourish microbial communities. Bifidobacterium longum subsp. infantis (or B. longum subsp. infantis) flourishes on HMOs, creating a gut ecosystem that is both robust and protective.
Researchers describe this selective feeding as a highly specific natural prebiotic mechanism. HMOs also moonlight as molecular decoys. They mimic receptor sites that pathogens like Campylobacter jejuni and norovirus usually target, shunting infections away from intestinal cells. In parallel, they quietly guide immune training, boosting dendritic cell maturity and modulating T-cell behaviour. It is gut health and immunity, co-engineered from the earliest days of life.
Infant formula: where it all started – and still rules
HMOs first grabbed headlines in the infant formula industry, where replicating breast milk biology is a constant mission. Brands began adding 2’-fucosyllactose (2’-FL) and blends of HMOs to formulas, encouraging gut microbiota development reminiscent of breastfeeding results. This wasn’t just nutrition – it was evolution, reimagined.
The market data underscores how far HMOs have come, although forecasts diverge significantly. Both Mordor Intelligence and Polaris Market Research peg the global HMO market at just under $300m for 2025. From there, the paths split: Mordor projects steady expansion to around $600m by 2030, a CAGR of roughly 15%, while Polaris anticipates a much sharper trajectory – reaching $1.82bn by 2034, at a CAGR above 22%. The gap highlights both the growth potential and the uncertainty still surrounding this fast-evolving category.
Across the board, infant formula still accounts for the lion’s share – often above 85–90% of demand, according to multiple industry reports.
Crossing age boundaries: HMOs for adults
Beyond infancy, HMOs are inching into adult nutrition – especially where gut barrier integrity or immune modulation is needed. Though research for adults is nascent, studies suggest promising outcomes such as improved microbiome recovery post-antibiotics, enhanced mucosal protection and systemic immune benefits. What’s driving this shift? A combination of rising consumer awareness of the microbiome, demand for evidencebased ingredients and advances in biotechnology enabling cost-efficient HMO synthesis. Functional beverages, synbiotic blends, and ‘gut-first’ nutrition bars are beginning to sport HMO claims, albeit at a premium.
The health potential of HMOs stems not just from their presence, but their diversity. Each HMO structure behaves differently in the gut and interacts with microbes or immune pathways in a unique way. In a 2024 review published in Frontiers in Pediatrics, Anita Wichmann and colleagues explained how combinations of structurally diverse HMOs can have synergistic benefits in early-life nutrition: “By combining structurally diverse HMOs composed of different monosaccharide building blocks (fucose, GlcNAc, sialic acid), a closer recapitulation of the composition of breastmilk is achieved and greater health benefits are expected, including increased beneficial gut bacteria, defence against a broader range of pathogens, and potentially enhanced cognitive development.”
This underscores why innovation is now exploring multi-HMO formulas that mirror the complexity of human milk – versus single-ingredient approaches.
Real-world applications of HMOs
Although infant formula remains the primary market for HMOs, the potential of these bioactive compounds extends beyond early nutrition.
Over the past few years, manufacturers and researchers have been exploring new ways to integrate HMOs into a range of health products, opening opportunities in nutraceuticals, specialist applications, and functional foods and beverages. For example, HMOs are increasingly appearing in adultfocused dietary supplements, where they play a role in supporting gut health and overall well-being.
By selectively feeding beneficial gut microbes, HMOs help restore microbiome balance, particularly in adults recovering from gut dysbiosis. For example, BASF’s portfolio of HMOs, including 2’-Fucosyllactose (2’-FL), has been incorporated into capsule-based supplements designed to enhance microbial diversity and digestive resilience.
In the US, wellness brands have begun to market HMO-containing blends as part of daily microbiome maintenance. Products such as Layer Origin’s SuperHMO synbiotic capsules combine multiple
HMOs with probiotics to create formulations that are tailored for gut health support, immune function and overall digestive wellness. The combination of HMOs and probiotics in a single supplement represents a significant step forward in synbiotic innovation, delivering both prebiotic substrates and beneficial bacteria in one convenient regimen.
Beyond general wellness, researchers are beginning to explore more specialised applications of HMOs. Early-stage clinical trials have examined their potential in sports nutrition, particularly among endurance athletes who often experience gut barrier disruption during prolonged or intense training. HMOs may help preserve intestinal integrity, support microbial balance and modulate inflammation, which can be critical in maintaining both performance and recovery.
While these applications are still in the experimental phase and have yet to reach the commercial market, they point towards emerging niche opportunities for HMO-enriched sports nutrition products.
HMOs are also increasingly finding their way into functional foods and beverages, providing consumers with convenient ways to support digestive and immune health through everyday diets. In June, Nestlé launched Sinergity across the Middle East and Latin America after rolling it out across Europe. It is a fortified milk product for early childhood that combines six HMOs with probiotics to deliver gut and immune benefits.
Across Europe, several smaller dairy brands have experimented with yoghurts enriched with HMOs, reflecting a rising demand for functional dairy products that promote microbiome health. Start-ups are also developing HMO-containing formats such as gummies, powders and ready-to-drink beverages, recognising that ease of use and taste appeal are critical factors in consumer adoption.
Indeed, these applications illustrate the versatility and growing significance of HMOs across multiple consumer health categories. From capsule-based nutraceuticals and synbiotic supplements to earlystage sports nutrition trials and functional food products, HMOs are emerging as a valuable tool for supporting gut health, immunity and overall wellness at different life stages.
Precision nutrition’s next act
Regulation remains a decisive factor in how quickly HMOs can expand beyond infant formula. Several HMOs, including 2’-FL, LNnT and 3-FL, have already been authorised as novel foods in the EU and deemed Generally Recognised As Safe (GRAS) in the US. However, regional variability persists: Asia has generally moved faster on approvals, while regulators in Europe and North America remain more measured. These differences shape not only market timelines but also the types of products that can realistically reach shelves.
However, HMOs have graduated from the academic halls and infant formula factories to the broader stage of wellness innovation. They bring precision prebiotic action, immune modulation and cross-age relevance. Markets project growth into the billion-dollar range by 2030 and beyond.
For food scientists, brand strategists and medical writers alike, HMOs are more than just molecules – they’re a symbol of what functional nutrition can become: grounded in biology, powered by technology and embraced by consumers who demand proof.
